American Association for Cancer Research
crc-22-0471-s02.pdf (448.19 kB)

Supplementary Table ST2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies

Download (448.19 kB)
journal contribution
posted on 2023-04-04, 02:01 authored by Andres Chang, Akil Akhtar, Lilin Lai, Victor M. Orellana-Noia, Susanne L. Linderman, Ashley A. McCook-Veal, Jeffrey M. Switchenko, Manpreet Saini, Rajesh M. Valanparambil, Kristie A. Blum, Pamela B. Allen, Mary Jo Lechowicz, Jason T. Romancik, Amy Ayers, Alyssa Leal, Colin B. O'Leary, Michael C. Churnetski, Katelin Baird, Melissa Kives, Jens Wrammert, Ajay K. Nooka, Jean L. Koff, Madhav V. Dhodapkar, Mehul S. Suthar, Jonathon B. Cohen, Rafi Ahmed

Supplemental Table 2. Clinical characteristics of NHL/CLL patients with high anti-spike IgG titers prior to booster vaccination


HHS | National Institutes of Health (NIH)

EU | Winship Cancer Institute (Winship Cancer Institute of Emory University)

American Society of Hematology (ASH)

Leukemia and Lymphoma Society (LLS)

EU | School of Medicine, Emory University (Emory University School of Medicine)



Limited data exist on antibody responses against current SARS-CoV-2 variants after booster vaccination in patients with NHL/CLL. We showed inferior antibody responses against Omicron variants after booster vaccination in these patients but some generated anti-Omicron titers. This stresses the importance of vaccinating patients with updated formulations.